炔诺酮治疗依托孕烯植入剂相关 prolonged 子宫出血(IMPLANET):一项随机对照试验
IMPLANET 是在巴西开展的多中心随机盲法对照试验,纳入使用依托孕烯植入剂至少 40 天且连续出血至少 7 天的 18 至 40 岁女性,比较口服醋酸炔诺酮 10 mg/天与安慰剂的止血效果与安全性。醋酸炔诺酮组用药不超过 7 片即止血的比例为 86.7%,高于安慰剂组的 48.9%(P<.001);但停药后出血复发时间更短(5.0 天 vs 10.5 天,P=.008)。
要点
- 连续使用不超过 7 片醋酸炔诺酮 10 mg/天止血率 86.7%,高于安慰剂组 48.9%(P<.001)。
- 醋酸炔诺酮组出血复发时间 5.0 天,短于安慰剂组的 10.5 天(P=.008)。
- 醋酸炔诺酮可有效安全地止住 prolonged 出血,但不能预防出血复发。
核心结论
- 短期使用醋酸炔诺酮 10 mg/天可有效且安全地止住依托孕烯植入剂使用者的 prolonged 出血,但不能预防出血复发。
研究设计与样本
- IMPLANET 为在巴西开展的多中心、随机、对照、盲法试验。
- 纳入使用依托孕烯植入剂至少 40 天、入组时连续子宫出血至少 7 天的 18 至 40 岁女性,且无异常子宫出血既往诊断并接受标准化评估排除继发原因。
- 参与者按区组随机接受口服醋酸炔诺酮 10 mg 或安慰剂每日一次,直至连续 2 天无出血或连续治疗满 30 天,以先发生者为准;210 天内最多可重复治疗 3 次。
- 样本量 86 例可提供 80% 把握度检测用药不超过 7 片后止血率 30% 的差异。
- 改良意向性分析纳入至少接受一剂随机治疗且随机后衣原体/淋球菌筛查阴性的参与者,共 90 例(每组 45 例)。
主要发现
- 用药不超过 7 片即止血的比例:醋酸炔诺酮组 86.7% vs 安慰剂组 48.9%(P<.001);校正基线不平衡后校正风险差 35.6%(95%CI 17.1%-54.0%,P<.001)。
- 用药不超过 14 片止血比例:醋酸炔诺酮组 91.1% vs 安慰剂组 64.4%(P=.002)。
- 治疗失败率:醋酸炔诺酮组 2.2% vs 安慰剂组 17.8%(P=.03);停止首次出血所需治疗天数中位数:醋酸炔诺酮组 3.0 天 vs 安慰剂组 5.0 天(P=.01)。
- 出血复发时间:醋酸炔诺酮组 5.0 天 vs 安慰剂组 10.5 天(P=.008);前 30 天内无出血天数:醋酸炔诺酮组 21.0 天 vs 安慰剂组 13.0 天(P=.007)。
- 试验参与时间:醋酸炔诺酮组 159.9 天 vs 安慰剂组 127.2 天(P<.001);提前终止率:醋酸炔诺酮组 33.3%(P=.09)。
关键数值与推荐
- 主要结局为用药不超过连续 7 片后止血的参与者比例。
- 次要结局包括用药不超过 14 片后止血比例、停止首次出血所需治疗天数、首次治疗后出血复发时间、前 30 天内无出血天数、治疗失败(用药 30 天后仍出血)、前 30 天后出血天数及无出血天数、安全性结局。
- 探索性结局包括研究参与时间和提前终止。
临床怎么用
- 原文结论为短期使用醋酸炔诺酮 10 mg/天可有效且安全地止住依托孕烯植入剂使用者的 prolonged 出血,但不能预防出血复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Additional progestogens are often used in some countries to stop prolonged bleeding in etonogestrel implant users, although no evidence currently supports this practice. OBJECTIVE: To evaluate the efficacy and safety of oral norethisterone acetate, also known as norethindrone acetate, at a dose of 10 mg/day for prolonged bleeding associated with etonogestrel implant use. STUDY DESIGN: IMPLANET is a randomized, controlled, blinded, multicenter trial conducted in Brazil. It included etonogestrel implant users aged 18 to 40 years who had been using the implant for at least 40 days and had experienced uterine bleeding for a minimum of 7 consecutive days at enrollment. Participants had no prior diagnosis of abnormal uterine bleeding and underwent a standardized evaluation to exclude a secondary cause for the current prolonged bleeding episode. Participants were block-randomized to receive 10 mg of oral norethisterone acetate or placebo daily until they experienced no bleeding for 2 consecutive days or completed 30 consecutive days of treatment, whichever occurred first. Participants could repeat treatment up to 3 times over 210 days. Participants reported bleeding via daily messages. The primary outcome was the proportion of participants who achieved bleeding cessation after using up to 7 consecutive pills. Secondary outcomes included the proportion of participants who achieved bleeding cessation after using up to 14 pills, treatment days required to stop the first bleeding episode, time to bleeding recurrence after the first treatment, bleeding-free days within the first 30 days, treatment failure (continued bleeding after 30 days of pill use), bleeding days and bleeding-free days after the first 30 days, and safety outcomes. Exploratory outcomes included study participation time and premature discontinuation. A sample size of 86 participants provided 80% power to detect a 30% in bleeding cessation rates after using a maximum of 7 pills. The modified intention-to-treat analysis included participants who received at least one dose of the randomized treatment and had a negative chlamydia/gonorrhea screen postrandomization. We used Chi-square and Wilcoxon tests for comparisons. The primary outcome was additionally analyzed using a multiple log-binomial regression to adjust for baseline imbalances (age, employment status, and marital status), with adjusted risk difference and 95% confidence intervals. RESULTS: Between September 2020 and May 2023, 114 participants were enrolled, 99 were randomized, and 90 (45 per group) were included in the modified intention-to-treat. Baseline characteristics were similar except for age, employment, and marital status. The norethisterone acetate group had a significantly higher percentage of participants who achieved bleeding cessation after using up to 7 pills than the placebo group (86.7% vs 48.9%, P<.001), even after adjusting for baseline imbalances (adjusted risk difference, 35.6% [95% confidence interval, 17.1%-54.0%], P<.001). Bleeding cessation using up to 14 pills was higher (91.1% vs 64.4%; P=.002) and treatment failure was lower (2.2% vs 17.8%; P=.03) in the norethisterone acetate group than in the placebo group, with fewer median treatment days to stop bleeding in the norethisterone acetate group (3.0 vs 5.0 days; P=.01). Compared to placebo, the norethisterone acetate group had a shorter time to bleeding recurrence (5.0 vs 10.5 days; P=.008), more bleeding-free days in the first 30 days (21.0 vs 13.0 days; P=.007), longer trial participation (159.9 vs 127.2 days; P <.001), and a lower discontinuation rate (33.3%; P=.09). CONCLUSION: Short-term use of 10 mg/day norethisterone acetate effectively and safely stopped prolonged bleeding in etonogestrel implant users. However, it does not prevent bleeding recurrence.
引用
- Andrade MCR, Yamaguti EMM, de Nadai MN, et al. Norethisterone for prolonged uterine bleeding associated with etonogestrel implant (IMPLANET): a randomized controlled trial. Am J Obstet Gynecol. 2025. PMID: 40885418. doi:10.1016/j.ajog.2025.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。